Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID3894]
In development
Reference number: GID-TA10777
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal will be rescheduled to align with latest regulatory expectations. Further information regarding the timelines for this appraisal will be available in due course.